|
Wednesday 5 October |
| |
|
|
|
16.00 - 16.15 |
|
Welcome:
Presentation of chairs, agenda, meeting logistics
Axel Pähler (Roche), Emre Isin (Servier), Marie Ahlqvist (AstraZeneca), Markus Walles (Novartis)
|
|
|
|
SESSION 1: How AMS can transforms the drug development paradigm (Chair: Markus Walles, Novartis)
|
|
16.15 - 17.00 |
|
Presentation 1: Accelerator Mass Spectrometry for the support of Microtracer Studies at Boehringer-Ingelheim: Current approaches and future perspectives
Stefan Blech and Bojan Bister, Boehringer Ingelheim
|
|
17.00 - 17.30 |
|
Presentation 2: Biotransformation of the novel myeloperoxidase inhibitor AZD4831 in preclinical species and humans
Ulrik Jurva, AstraZeneca
|
|
17.30 - 18.00 |
|
Presentation 3: AMS in biotransformation studies: Unusual case studies
Axel Paehler, Roche
|
|
18.00 - 18.15 |
|
Coffee break
|
|
18.15 - 19.00 |
|
Discussion on new FDA draft guidance and AMS (All)
- standard radioactivity vs microtrace
- alternative technologies cavity ring down/F-NMR
- comments on placement of hADME study (early/late)
- new clinical study designs
|
|
|
|
|
|
19.30 - 21.00 |
|
Dinner in Movenpick restaurant
|
|
|
|
End of first day
|
|
|
|
|
|
Thursday 6 October |
|
|
|
|
|
|
|
SESSION 2: Multimodal molecular imaging and ion mobility applications in drug discovery and development (Chair: Emre Isin, Servier)
|
|
09.00 - 09.30 |
|
Presentation 4: Multimodal molecular imaging in drug discovery and development
Georges DaViolante, Servier
|
|
09.30 - 10.00 |
|
Presentation 5: Ion mobility-enabled approaches to DMPK challenges
Russell Mortishire-Smith, Waters
|
|
10.00 - 10.30 |
|
Presentation
6: The potential of predicted, measured and relative CCS values for
metabolite assignment and tracking
Christian Lanshoeft, Novartis
|
|
10.30 - 11.00 |
|
Waters sponsored coffee break
|
|
11.00 - 11.30 |
|
Discussion on new technologies (MS imaging/ion mobility) (All)
|
|
11.30 - 13.00 |
|
Lunch (Movenpick restaurant)
|
|
|
|
SESSION 3: MIST of large molecules (Chair: Marie Ahlqvist, AstraZeneca)
|
|
13.00 - 13.30 |
|
Presentation 7: PEG related MIST aspects to a general discussion of MIST of large molecules
Lloyd King, UCB
|
|
13.30 - 14.00 |
|
Presentation 8: An industry perspective on therapeutic protein biotransformation
Markus Walles, Novartis
|
|
14.00 - 14.30 |
|
Discuss potential MIST issues of large molecules (All)
Is it relevant?
|
|
14.30 - 14.45 |
|
Ideas/topics for 4th European Biotransformation Workshop (All)
|
|
14.45 - 15.00 |
|
Meeting close
|